FDA approves Linzess for irritable bowel syndrome, constipation

- Yakima, Our Home
- NW Bird Pics

Updated:

HealthMore>>
Many U.S. adults under-vaccinated against whooping cough
Many U.S. adults under-vaccinated against whooping cough
Whooping cough cases are escalating in the United States, and many American adults are unknowingly exposing vulnerable babies to the potentially deadly disease because their vaccinations are not up to date.More >>
Whooping cough cases are escalating in the United States, and many American adults are unknowingly exposing vulnerable babies to the potentially deadly disease because their vaccinations are not up to date.More >>
A deadly form of diabetes that doctors sometimes miss
A deadly form of diabetes that doctors sometimes miss
Addie Parker was a happy 4-year-old who appeared to have the flu. But within hours she was in a coma.More >>
Addie Parker was a happy 4-year-old who appeared to have the flu. But within hours she was in a coma.More >>
Gene variants may play role in obesity
Gene variants may play role in obesity
Two new studies offer some solace to those who can't control their weight despite diet and exercise by providing more evidence that genetics may play a role in obesity.More >>
Two new studies offer some solace to those who can't control their weight despite diet and exercise by providing more evidence that genetics may play a role in obesity.More >>

THURSDAY, Aug. 30 (HealthDay News) -- Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome accompanied by constipation, the agency said Thursday in a news release.

The National Institutes of Health estimates that some 63 million people are affected by chronic constipation, and about 15.3 million have irritable bowel syndrome (IBS), the FDA said.

Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.

The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.

Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.

More information

Medline Plus has more about constipation.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.

FDA approves Linzess for irritable bowel syndrome, constipation - NBC Right Now/KNDO/KNDU Tri-Cities, Yakima, WA |

FDA approves Linzess for irritable bowel syndrome, constipation

HealthMore>>

Many U.S. adults under-vaccinated against whooping cough

Many U.S. adults under-vaccinated against whooping cough

A deadly form of diabetes that doctors sometimes miss

A deadly form of diabetes that doctors sometimes miss

Gene variants may play role in obesity

Gene variants may play role in obesity